Express Scripts’ annual Drug Trend Report highlights top contributors to prescription drug spending in 2019.
The first FDA-approved product for NASH on the horizon.
A new class of drugs for high cholesterol and a novel peanut allergy treatment lead expected approvals.
The first respiratory biologic to be approved for administration via an autoinjector will be available in the US soon.
The value and benefits of biosimilars are increasingly becoming more apparent. Here are four areas where they are growing the most.
In the past week, the migraine prevention drug market has suddenly heated up, with 2 new approvals by FDA.
Experts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.
Albert A. Rizzo, MD, senior medical advisor for the American Lung Association, says the increasing number of drugs in the pipeline could improve airflow and address the underlying disease process.
A new study has unbelievable findings about treating Medicare patients with diabetes.
A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.